An Update on Monoclonal Antibody Therapies in Multiple Sclerosis
An Update on Monoclonal Antibody Therapies in Multiple Sclerosis
复制标题
DOI：
10.1177/0897190007305147
复制
发表时间：
2007-04
影响因子：
1.3
通讯作者：
Bilal A. Choudry;J. Chan
中科院分区：
文献类型：
--
作者：
Bilal A. Choudry;J. Chan
Multiple sclerosis (MS) is a complex disease that causes a great deal of disability, especially in the young adult population. There have been several immunomodulatory agents that have been approved by the Food and Drug Administration for MS, including glatiramer acetate, interferon-β1a and -β1b, mitoxantrone, and corticosteroids. The effectiveness of these therapies has not been optimal, and drugs, such as monoclonal antibodies, that more selectively target the pathogenetic process of MS have been sought. These agents have their own intrinsic limitations such as systemic inflammatory reactions, induction of neutralizing antiantibodies, and even life-threatening infectious processes. The agent that has been in the forefront of the discussion is natalizumab, a monoclonal antibody (mAb) against α4 integrin, which shows much promise in suppressing MS activity. However, 3 individuals treated with natalizumab developed a life-threatening infection, progressive multifocal leukoencephalopathy. This article reviews the role of mAbs in the treatment of MS, particularly their advantages over other drugs and their limitations, which have to be overcome for these agents to be at the forefront in the treatment of MS.
